Fully Enrolled Confirmatory Studies Can De-Risk Novel Accelerated Approval Endpoints – FDA Official

 
• By Sarah Karlin-Smith
pencil erasing word risk
Novel cancer endpoints may get more regulatory leeway in context of Project Frontrunner • Source: Shutterstock

More from Clinical Trials

More from R&D